CLAIMS

1. A solid preparation comprising:

2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide; and

D-mannitol having a specific surface area of larger than 0.2 m^2/g, and 1.0 m^2/g or less;

wherein the content of D-mannitol is:

(a) such that the weight of D-mannitol is from 5 to 10000 parts by weight with respect to 1 part by weight of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide,

(b) from 10 to 99 wt% of the total weight of the solid preparation, and

(c) 20 wt% or more of the total weight of diluents contained in the solid preparation.

2. The solid preparation according to claim 1, further comprising a diluent other than D-mannitol and a binder.

3. The solid preparation according to claim 2, wherein the diluent other than D-mannitol is one type or two types selected from the group consisting of cornstarch, sucrose, and crystalline cellulose.

4. The solid preparation according to claim 2, wherein the binder is hydroxypropyl cellulose.

5. The solid preparation according to claim 1, further comprising:

(d) one type or two types selected from the group consisting of cornstarch, sucrose, and crystalline cellulose; and

(e) hydroxypropyl cellulose.

6. The solid preparation according to claim 5, wherein

(f) the content of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide is from 0.1 to 2 wt% of the total weight of the solid preparation,

(b) the content of D-mannitol is from 20 to 80 wt% of the total weight of the solid preparation,

(g) the content of cornstarch is from 15 to 40 wt% of the total weight of the solid preparation, and

(h) the content of hydroxypropyl cellulose is from 1 to 5 wt% of the total weight of the solid preparation.

7. The solid preparation according to claim 1, wherein 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide is a Form-I crystal.

8. The solid preparation according to claim 1, wherein the solid preparation is a tablet or a granule.

9. Use of the solid preparation according to claim 1 in the manufacture of a medicament for treating diabetic neuropathy, diabetic gangrene, a peripheral circulatory

disturbance, chronic arterial occlusion, intermittent claudication, scleroderma, thrombosis, pulmonary hypertension, myocardial infarction, angina pectoris, glomerulonephritis, diabetic nephropathy, chronic renal failure, bronchial asthma, interstitial pneumonia, a chronic obstructive pulmonary disease, tubulointerstitial nephritis, an inflammatory bowel disease, or a symptom associated with spinal canal stenosis.

10. The use according to claim 9, wherein the medicament is for treating pulmonary hypertension.

11. The use according to claim 9, wherein the medicament is for treating a peripheral circulatory disturbance.

12. The use according to claim 9, wherein the medicament is for treating chronic arterial occlusion.

13. The use according to claim 9, wherein the medicament is for treating intermittent claudication.

14. The use according to claim 9, wherein the medicament is for treating a symptom associated with spinal canal stenosis.

15. The use according to claim 9, wherein the medicament is for treating interstitial pneumonia and the interstitial pneumonia is pulmonary fibrosis.

16. The use according to claim 9, wherein the medicament is for treating scleroderma.

17. The use according to claim 9, wherein the medicament is for treating chronic renal failure.

18. The use according to claim 9, wherein the medicament is for treating tubulointerstitial nephritis.

19. The use according to claim 10, wherein the pulmonary hypertension to be treated is pulmonary arterial hypertension.

20. The use according to claim 19, wherein the solid preparation further comprises a diluent other than D-mannitol and a binder.

21. The use according to claim 19, wherein the solid preparation further comprises:

(d) one type or two types selected from the group consisting of cornstarch, sucrose, and crystalline cellulose; and

(e) hydroxypropyl cellulose.

22. The use according to claim 21, wherein the solid preparation comprises cornstarch, and

(f) the content of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide is from 0.1 to 2 wt% of the total weight of the solid preparation,

(b) the content of D-mannitol is from 20 to 80 wt% of the total weight of the solid preparation,

(g) the content of cornstarch is from 15 to 40 wt% of the total weight of the solid preparation, and

(h) the content of hydroxypropyl cellulose is from 1 to 5 wt% of the total weight of the solid preparation.

23. The use according to claim 19, wherein the medicament is a tablet.

24. The use according to claim 23, wherein D-mannitol has a specific surface area of larger than 0.2 m^2/g and smaller than 0.7 m^2/g, and the content of D-mannitol is:

(a) such that the weight of D-mannitol is from 10 to 9500 parts by weight with respect to 1 part by weight of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide,

(b) from 20 to 80 wt% of the total weight of the solid preparation, and

(c) 50 wt% or more of the total weight of diluents contained in the solid preparation.

25. The use according to claim 24, wherein the solid preparation further comprises:

(d) one type or two types selected from the group consisting of cornstarch, sucrose, and crystalline cellulose; and

(e) hydroxypropyl cellulose.

26. The use according to claim 25, wherein the solid preparation comprises cornstarch, and

(f) the content of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide is from 0.1 to 2 wt% of the total weight of the solid preparation,

(g) the content of cornstarch is from 15 to 40 wt% of the total weight of the solid preparation, and

(h) the content of hydroxypropyl cellulose is from 1 to 5 wt% of the total weight of the solid preparation.

27. The solid preparation according to claim 1 for use in treating diabetic neuropathy, diabetic gangrene, a peripheral circulatory disturbance, chronic arterial occlusion, intermittent claudication, scleroderma, thrombosis, pulmonary hypertension, myocardial infarction, angina pectoris, glomerulonephritis, diabetic nephropathy, chronic renal failure, bronchial asthma, interstitial pneumonia, a chronic obstructive pulmonary disease, tubulointerstitial nephritis, an inflammatory bowel disease, or a symptom associated with spinal canal stenosis.

28. The solid preparation for use according to claim 27, wherein the solid preparation is for use in treating pulmonary hypertension.

29. The solid preparation for use according to claim 27, wherein the solid preparation is for use in treating a peripheral circulatory disturbance.

30. The solid preparation for use according to claim 27, wherein the solid preparation is for use in treating chronic arterial occlusion.

31. The solid preparation for use according to claim 27, wherein the solid preparation is for use in treating intermittent claudication.

32. The solid preparation for use according to claim 27, wherein the solid preparation is for use in treating a symptom associated with spinal canal stenosis.

33. The solid preparation for use according to claim 27, wherein the solid preparation is for use in treating interstitial pneumonia and the interstitial pneumonia is pulmonary fibrosis.

34. The solid preparation for use according to claim 27, wherein the solid preparation is for use in treating scleroderma.

35. The solid preparation for use according to claim 27, wherein the solid preparation is for use in treating chronic renal failure.

36. The solid preparation for use according to claim 27, wherein the solid preparation is for use in treating tubulointerstitial nephritis.

37. The solid preparation for use according to claim 28, wherein the pulmonary hypertension to be treated is pulmonary arterial hypertension.

38. The solid preparation for use according to claim 37, wherein the solid preparation further comprises a diluent other than D-mannitol and a binder.

39. The solid preparation for use according to claim 37, wherein the solid preparation further comprises:

(d) one type or two types selected from the group consisting of cornstarch, sucrose, and crystalline cellulose; and

(e) hydroxypropyl cellulose.

40. The solid preparation for use according to claim 39, wherein the solid preparation comprises cornstarch, and

(f) the content of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide is from 0.1 to 2 wt% of the total weight of the solid preparation,

(b) the content of D-mannitol is from 20 to 80 wt% of the total weight of the solid preparation,

(g) the content of cornstarch is from 15 to 40 wt% of the total weight of the solid preparation, and

(h) the content of hydroxypropyl cellulose is from 1 to 5 wt% of the total weight of the solid preparation.

41. The solid preparation for use according to claim 37, wherein the solid preparation is a tablet.

42. The solid preparation for use according to claim 41, wherein D-mannitol has a specific surface area of larger than 0.2 m^2/g and smaller than 0.7 m^2/g, and the content of D-mannitol is:

(a) such that the weight of D-mannitol is from 10 to 9500 parts by weight with respect to 1 part by weight of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide,

(b) from 20 to 80 wt% of the total weight of the solid preparation, and

(c) 50 wt% or more of the total weight of diluents contained in the solid preparation.

43. The solid preparation for use according to claim 42, wherein the solid preparation further comprises:

(d) one type or two types selected from the group consisting of cornstarch, sucrose, and crystalline cellulose; and

(e) hydroxypropyl cellulose.

44. The solid preparation for use according to claim 43, wherein the solid preparation comprises cornstarch, and

(f) the content of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide is from 0.1 to 2 wt% of the total weight of the solid preparation,

(g) the content of cornstarch is from 15 to 40 wt% of the total weight of the solid preparation, and

(h) the content of hydroxypropyl cellulose is from 1 to 5 wt% of the total weight of the solid preparation.